Altre lingue Cognition Therapeutics, Inc.

Azioni

CGTX

US19243B1026

Mercato chiuso - Nasdaq Altri mercati azionari 19:00:00 03/07/2024			Variaz. 5gg	Var. 1 gen.
1,77 ^USD	-2,75%		+0,57%	-4,32%

02/07	Cognition Therapeutics, Inc. annuncia che i risultati dello studio di Fase 2 Shine di Cognition Therapeutics su CT1812 nella malattia di Alzheimer lieve-moderata sono stati accettati per la presentazione all'AAIC	CI
07/06	COGNITION THERAPEUTICS, INC. : Chardan Research ottimista sul caso	ZM

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC	02/07
Cognition Therapeutics, Inc. Announces Results from Cognition Therapeutics' Phase 2 Shine Study of CT1812 in Mild-To-Moderate Alzheimer's Disease Accepted for Presentation at AAIC	02/07
Cognition Therapeutics : CGTX Corporate Deck	13/06
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease	21/05
Cognition Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update	07/05
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	29/04
Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	29/04
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's disease	23/04
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease	22/04
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference	02/04
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024	01/04
Cognition Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update	26/03
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results	15/03
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results	15/03
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock	14/03
Cognition Therapeutics Prices $11.5 Million Stock Offering	12/03
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock	12/03
Cognition Therapeutics Starts Public Offering; Shares Decline	11/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Cognition Therapeutics, Inc.

Azioni

CGTX

US19243B1026

Altre lingue

Filtri